Evidence map›Paper›PMID 42558954›Full record

ArticleIJU case reports2026

Deferred Cytoreductive Nephrectomy With Partial Hepatectomy for Giant Renal Cell Carcinoma of the Right Kidney With Extensive Hepatic Invasion: A Case Report in the Era of Systemic Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors.

Yuki Hiroshi, Takamitsu Inoue, Takuya Minagawa, Masaki Takahashi, Akinobu Katami, Mizuki Onozawa, Masahiro Shinoda, Osamu Itano, Jun Miyazaki

Abstract read
In one paragraph

Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuki HiroshiDepartment of Renal and Urological Surgery International University of Health and Welfare Narita Hospital Narita Japan.ORCID https://orcid.org/0009-0006-8043-9305
Takamitsu InoueDepartment of Renal and Urological Surgery International University of Health and Welfare Narita Hospital Narita Japan.ORCID https://orcid.org/0000-0002-1362-4344
Takuya MinagawaDepartment of Hepato-Biliary-Pancreatic & Gastrointestinal Surgery International University of Health and Welfare Narita Hospital Narita Japan.ORCID https://orcid.org/0000-0003-0860-1591
Masaki TakahashiDepartment of Renal and Urological Surgery International University of Health and Welfare Narita Hospital Narita Japan.
Akinobu KatamiDepartment of Renal and Urological Surgery International University of Health and Welfare Narita Hospital Narita Japan.ORCID https://orcid.org/0009-0009-3100-8375
Mizuki OnozawaDepartment of Renal and Urological Surgery International University of Health and Welfare Narita Hospital Narita Japan.ORCID https://orcid.org/0000-0001-9700-0274
Masahiro ShinodaDepartment of Hepato-Biliary-Pancreatic & Gastrointestinal Surgery International University of Health and Welfare Narita Hospital Narita Japan.ORCID https://orcid.org/0000-0002-4315-9244
Osamu ItanoDepartment of Hepato-Biliary-Pancreatic & Gastrointestinal Surgery International University of Health and Welfare Narita Hospital Narita Japan.ORCID https://orcid.org/0000-0002-2197-9508
Jun MiyazakiDepartment of Renal and Urological Surgery International University of Health and Welfare Narita Hospital Narita Japan.ORCID https://orcid.org/0000-0002-3618-0432

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Deferred cytoreductive nephrectomy may improve the prognosis of patients with metastatic renal cell carcinoma (RCC). However, reports of combined hepatic resection for RCC with liver invasion are limited, and treatment strategies remain insufficiently established. Case Presentation: A 75-year-old man presented with right RCC with liver invasion, lung metastases, and an inferior vena cava (IVC) tumor thrombus. Nivolumab plus cabozantinib reduced the lung metastases but not the primary tumor or thrombus. Three months after starting systemic therapy, he underwent open right nephrectomy, partial hepatectomy of segments 5, 6, 7, and part of 8, and tumor thrombus resection. Pathology revealed pT4, Grade 4 clear cell carcinoma. Although lung metastases recurred postoperatively, systemic therapy was resumed on day 51, resulting in complete remission. Conclusion: Appropriately early cytoreductive nephrectomy with partial hepatectomy after systemic therapy may have contributed to this favorable outcome.

Indexed as

cytoreductive nephrectomyliver invasionnivolumab and cabozantinib combination therapyrenal cell carcinomatumor thrombus

Identifiers

PMID42558954
PMCPMC13439213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.